At siRNAgen Therapeutics, we specialize in the development of rodent disease models and provide comprehensive preclinical services to support the evaluation of novel drug candidates. With deep expertise in RNAi-based therapeutics, we offer a full suite of in vivo efficacy and histopathological analysis services designed to help accelerate your drug development pipeline.
We identify and provide the most efficient candidate compounds targeting your gene of interest, accompanied by a comprehensive experimental report detailing material information, testing methods, procedures, and all relevant data. We are offering our customized RNAi drug high-throughput screening service.
Whether you are exploring anti-inflammatory agents, oncology targets, or rare disease therapeutics, our in vivo platforms offer robust, reproducible, and translationally relevant data.
We welcome individual or separate inquiries for collaborative projects or specialized study designs.

• Rodent Disease Model Development
• In Vivo Efficacy Testing
• Histopathology Services Using Rodent Tissues
• Targeted gene silencing studies using siRNA
• Detailed reporting to support IND-enabling studies

Custom generation of disease models in mice and rats for a wide range of indications, including inflammation, oncology, and metabolic diseases.

Evaluation of client-derived therapeutic candidates using clinically relevant models and readouts.

Expert tissue processing, sectioning, staining (e.g., H&E, IHC), and microscopic examination conducted by certified pathologists.
Detailed histological assessments to support efficacy, toxicity, and biomarker evaluation.

Functional validation of therapeutic targets through siRNA-mediated knockdown and downstream biomarker analysis.

IND-enabling documentation including raw data, statistical analysis, and professional interpretation of results.